1 Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.
2 Departments of Pediatrics, Hamad Medical Center, Doha, Qatar.
3 Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
β-thalassemia intermedia (TI) spans a wide spectrum of severity and
carries higher morbidity than previously recognized, including
extramedullary hematopoiesis, leg ulcers, gallstones, thrombosis,
secondary heart failure, pulmonary hypertension, skeletal deformity,
growth retardation and endocrine abnormalities, such as diabetes
mellitus, hypothyroidism, osteoporosis, and hypogonadism.
Patients and Methods
|Table 1. Patients’ characteristics and biochemical parameters in 28 patients with β-thalassemia intermedia|
|Table 2. Final adult height (Ht-SDS), endocrine complications, biochemical parameters and bone densitometry in 28 patients withβ-thalassemia intermedia.|
|Figure 1. Correlation between liver iron concentration (LIC) and serum ferritin (r = 0.47; P: 0.01).|
|Figure 2. Correlation between standing height - SDS (Ht-SDS) and insulin growth factor- 1 SDS (IGF1SDS) (r = 0.65; P: < 0.001).|
|Table 3. Correlations (r values) between anthropometric and biochemical variables in patients with β-thalassemia intermedia.|